KRAS and lung carcinoma: Furthermore, we demonstrate that SHP2 inhibition potently leads to the induction of TGFβ, suggesting that combination therapy with SHP2 inhibitors and TGFβ inhibitors should be considered in lung cancer patients with activated KRAS.